Schütz Harald, Auch Jürgen, Erdmann Freidoon, Weiler Günter, Verhoff Marcel A
Institut für Rechtsmedizin, Klinikum Giessen-Marburg, Giessen, Germany.
Arzneimittelforschung. 2006;56(6):414-20. doi: 10.1055/s-0031-1296743.
Immunoassays are used worldwide for the rapid screening of drugs. Despite the fact that they are highly valuable tools for the testing of legal and illicit drugs, there is a non-negligable risk of false-positive and false-negative findings and many pitfalls must be taken into account when using these tests in an uncritical manner and without valid confirmation procedures. In order to check the correlation between cloned-enzyme donor immunoassay (CEDIA) readings and exact determined gas chromatography/mass spectrometry (GC/MS) values for benzoylecgonine, a total of 472 serum samples was measured with an immunoassay (CEDIA) as well as GC/MS. As a result, it was shown that in the lower area of concentration, up to approx. 300 ng equ. benzoylecgonine/ml, there is a semiquantitative useful correlation. With higher concentrations, the values shift more and more apart and many runaways are visible. Generally the use of tests for materials other than those declared is excluded from the manufacturer's warranty and is at the user's own risk, but the authors found that many immunochemical tests with a certification only for the use in urine are well suited to the screening of serum samples, and even low readings could be confirmed by GC/MS. With blood or serum as sample, it could be regularly observed that generally very small readings could not only be confirmed with mass spectrometry but could in most cases also be quantified. This was the key factor in determining the rate of confirmation in 495 cases. In total, an incredibly high reliability for the CEDIA cocaine test (via benzoylecgonine) was shown up to the area of detection (detection limit), far below the cut-off. These results confirm the extraordinary sensitivity and specificity of this test also for blood or serum as sample material to be tested.
免疫测定法在全球范围内用于药物的快速筛查。尽管它们是检测合法和非法药物的非常有价值的工具,但存在不可忽视的假阳性和假阴性结果的风险,并且在不加批判地使用这些测试且没有有效的确认程序时,必须考虑到许多陷阱。为了检查克隆酶供体免疫测定法(CEDIA)读数与苯甲酰芽子碱的确切气相色谱/质谱(GC/MS)值之间的相关性,使用免疫测定法(CEDIA)以及GC/MS对总共472份血清样本进行了测量。结果表明,在较低浓度范围内,高达约300 ng当量苯甲酰芽子碱/毫升,存在半定量的有用相关性。随着浓度升高,数值越来越分散,出现了许多失控情况。一般来说,使用测试未声明的材料不在制造商的保修范围内,由用户自行承担风险,但作者发现许多仅认证用于尿液检测的免疫化学测试非常适合血清样本的筛查,甚至低读数也可以通过GC/MS得到确认。以血液或血清作为样本,可以经常观察到,通常非常低的读数不仅可以通过质谱法得到确认,而且在大多数情况下还可以进行定量。这是确定495例确认率的关键因素。总体而言,在检测区域(检测限)内,CEDIA可卡因测试(通过苯甲酰芽子碱)显示出令人难以置信的高可靠性,远低于临界值。这些结果证实了该测试对于作为待检测样本材料的血液或血清也具有非凡的灵敏度和特异性。